It should be noted that in cell lines as different as human neuroblastoma, glioma, retinoblastoma, larynx carcinoma, and leukaemia the same NK-1 receptor antagonist (L-733,060,L-732,138, or aprepitant) elicits growth inhibition. This evidence concerns the gene TACR1 and central nervous system cancer.